Ask about this productRelated genes to: PCBP2 Blocking Peptide
- Gene:
- PCBP2 NIH gene
- Name:
- poly(rC) binding protein 2
- Previous symbol:
- -
- Synonyms:
- HNRPE2, hnRNP-E2, HNRNPE2
- Chromosome:
- 12q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1996-06-07
- Date modifiied:
- 2015-09-03
Related products to: PCBP2 Blocking Peptide
Related articles to: PCBP2 Blocking Peptide
- Triple-negative breast cancer (TNBC), characterized by the absence of effective therapeutic targets, remains a major clinical challenge with poor prognosis. The identification of novel molecular targets is therefore crucial for developing effective treatment strategies. Eukaryotic elongation factor 2 kinase (eEF2K) is highly expressed in TNBC and known to promote tumor progression; however, the precise mechanisms underlying its oncogenic role remain elusive. In this study, we identified poly(rC)-binding protein 2 (PCBP2) as a previously unrecognized downstream substrate of eEF2K. Analysis of clinical TNBC specimens revealed a positive correlation between eEF2K and PCBP2 protein expression levels. Further studies demonstrated that site-specific phosphorylation of PCBP2 at serine 189 (Ser189) markedly promoted the malignant phenotype of TNBC cells. Mechanistically, eEF2K-mediated phosphorylation at Ser189 stabilized PCBP2 by preventing its ubiquitin-proteasome-dependent degradation. This phosphorylation-dependent stabilization, in turn, enabled PCBP2 to promote the mRNA stability of pro-oncogenic genes, including TNC, SOX5, and ITGB3, thereby driving TNBC progression. Collectively, these findings not only reveal PCBP2 as a critical downstream effector of eEF2K, but also highlight the eEF2K-PCBP2 signaling axis as a promising therapeutic target for TNBC. - Source: PubMed
Publication date: 2026/03/25
Cheng YueyingJiang TingZhu WenqianHe LinhaoChen ZonglingLi HangZhao RuigangJiang ShilongCheng Yan - Myocardial ischemia/reperfusion (I/R) injury is a major contributor to coronary heart disease. Fasting has emerged as a cardioprotective intervention, yet the underlying mechanisms are unclear. Ferroptosis, an iron-dependent form of regulated cell death, has been implicated in I/R injury, but its interplay with fasting in the myocardial context has yet to be determined. - Source: PubMed
Publication date: 2026/04/16
Han RuijuanXie JiananZhou ShanshanZhang XiaopingSun Kai - - Source: PubMed
Publication date: 2026/04/09
Li FangZhang ZhaoLiu ShuaiWang YangDeng XiangWang Jiasheng - Expression of poly(rC)-binding protein 2 (PCBP2) is altered in various cancers. This study aimed to assess its role in the development of the malignant phenotype in cholangiocarcinoma (CCA) cells. PCBP2 mRNA levels in CCA (n = 35) and adjacent non-tumor (NT) tissue (n = 9) were analyzed in silico using the TCGA-CHOL database. PCBP2 expression was also measured experimentally (RT-qPCR, WB, and IHC) in clinical samples from intrahepatic CCA (iCCA; n = 17), extrahepatic CCA (eCCA; n = 17), and NT tissue (n = 14). The relationship of PCBP2 expression with clinicopathological features was investigated. The PCBP2 gene was silenced in CCA-derived cells using lentiviral vectors carrying shRNAs. After transduction, cell viability (MTT assay), colony formation (crystal violet staining), cell cycle (flow cytometry), proliferation and migration (holographic microscopy), and transcriptome profiling (RNA-seq) were assessed. The results indicated that PCBP2 was highly expressed in CCA and that its expression correlated with metastasis and poor progression-free survival. Silencing PCBP2 in CCA cells did not alter the response to anti-CCA drugs (cisplatin, oxaliplatin, gemcitabine, 5-fluorouracil, and sorafenib) but reduced cell viability and proliferation, impaired colony formation, and inhibited migration. Transcriptomic analysis following PCBP2 silencing revealed the downregulation of several oncogenic genes (DHRS3, NRP2, MEX3A, and PCGF2). Electrophoretic mobility shift assay (EMSA) demonstrated that PCBP2 binds to the DHRS3 3'UTR, suggesting a role for PCBP2 in the post-transcriptional regulation of its target genes. In conclusion, PCBP2 promotes the malignant phenotype in CCA, highlighting its potential as a target for the development of future pharmacological treatments for patients with this cancer. - Source: PubMed
Publication date: 2026/03/22
Reviejo MariaLozano ElisaMendez RaulGonzalez Luis MMacias Rocio I RBriz OscarMarin Jose J GAsensio Maitane - Colorectal cancer (CRC) ranks as the third most common malignancy worldwide. Cyclin dependent kinase inhibitor 2A (CDKN2A) is a key regulatory gene in the recently identified cell death pathway known as cuproptosis. The small nucleolar RNA host gene 7 (SNHG7) is an important and versatile molecule engaged in a variety of tumorigenic processes. Poly(rC)-binding protein 2 (PCBP2) is an RNA-binding protein that enhances RNA stability and is implicated in the progression of various tumors. However, the clinical role of cuproptosis-related SNHG7 in CRC largely remains unclear. We conducted cell culture and subcutaneous tumor formation experiments in nude mice, followed by qPCR, Western blotting, RNA immunoprecipitation, lactate production assays, gel electrophoresis, and immunohistochemistry on the corresponding tissues. Our results demonstrate that SNHG7 interacts with PCBP2 to enhance the expression of CDKN2A, thereby modulating cuproptosis and promoting glycolysis. These findings suggest that SNHG7 represents a promising therapeutic target for CRC. - Source: PubMed
Publication date: 2026/03/23
Chen QiusanSong QiuyuZhang HaonanLin ZhaoxianShi YuluChai YixiaFang XianmeiLi NaZheng YifengYang YiWu XueYingWang ShanpingHe ChengchengLi Mingsong